Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (9989.HK) Stock Forecast & Price Predictions
Get the latest Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (9989.HK) stock forecast across short-term and long-term horizons. Meyka AI generates price predictions using advanced models trained on historical data. These forecasts are not investment advice but directional insights to help investors and traders plan strategies.
Model Information
The Forecast Prediction Model is provided for informational purposes only and should not be considered financial advice. We are continously improving this model to increase accuracy and performance.Read our Full DisclaimerMonthly Forecast
Quarterly Forecast
Yearly Forecast
3 Years Forecast
5 Years Forecast
7 Years Forecast
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Stock Forecast Summary
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (9989.HK) stock is currently priced at $5.08. Based on Meyka AI predictions, the short-term outlook is bullish, with momentum pointing higher. The 1-month projection suggests a move toward $5.14.
In the long term, 9989.HK shows a bullish trend. The 2027 forecast points to $7.31 (43.91% change), while the 2031 forecast suggests $13.71 (169.79% change). Looking 7 years ahead, projections estimate the stock could trade near $16.92, a 233.10% change from today’s price.
Bullish
Bullish
Bullish
This mix indicates that Shenzhen Hepalink Pharmaceutical Group Co., Ltd. stock is expected to rise steadily over the coming years.
Investment Calculator
Estimate your potential returns on 9989.HK based on our AI price forecasts. Enter your investment amount and select a target date.
Based on your investment of HK$1,000.00 in Shenzhen Hepalink Pharmaceutical Group Co., Ltd. and holding until April 5th, 2027, you could make a potential +HK$439.08 profit, reflecting a +43.9% ROI over the next 365 days.
$Shares Bought
196.8504
@ HK$5.08/share
~Forecast Price
HK$7.31
1-year AI forecast
$Est. Portfolio Value
HK$1,439.08
+HK$439.08 profit
%ROI
+43.9%
return on investment
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. yearly Price Forecast Chart
Explore the yearly forecast chart for 9989.HK, which maps expected price movement, support levels, and resistance targets. The dropdown lets you view forecasts across multiple horizons, from short-term daily trends to 7-year projections, helping investors evaluate Shenzhen Hepalink Pharmaceutical Group Co., Ltd. over different timeframes.
No forecast data available
No prediction data found for this time period.
Forecasting data is not available for 9989.HKForecasting details for 9989.HK are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Stock Forecast 2026
The forecast for Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (9989.HK) in 2026 suggests a price of $7.31, representing a 43.91% move from today’s price.
Average Target: $7.31
Market Outlook: bullish based on current trend indicators.
Key Drivers in 2026:- Earnings growth projections.
- Competitive performance in the Healthcare.
- Macroeconomic factors such as interest rates and inflation.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Stock Forecast 2030
By 2030, Meyka AI projects 9989.HK could trade near $13.71, showing a potential 169.79% compared to current levels.
Average Target: $13.71
Market Outlook: bullish.
What could influence the 2030 forecast:- Technological innovation and product cycles.
- Expansion into global markets.
- Long-term investor sentiment toward Shenzhen Hepalink Pharmaceutical Group Co., Ltd..
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. 7-Year Stock Forecast (2032–2033)
Looking 7 years ahead, the long-term forecast for 9989.HK points to a price around $16.92, which is a projected 233.10% move from today’s level.
Average Target: $16.92
Outlook: bullish, depending on macroeconomic conditions and sector growth.
Long-Term Drivers:- Global economic expansion or contraction.
- Regulatory and policy environment.
- Shenzhen Hepalink Pharmaceutical Group Co., Ltd.’s ability to maintain market leadership.